Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes

Jacob E. Ollech; Irit Avni-Biron; Laura Glick; Haider Haider; Sushila R. Dalal; Dejan Micic; Joel Pekow; Henit Yanai; Russel D. Cohen; Iris Dotan; David T. Rubin; Atsushi Sakuraba

doi:10.1016/j.cgh.2020.10.035

Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes

Jacob E. Ollech^*, Irit Avni-Biron, Laura Glick, Haider Haider, Sushila R. Dalal, Dejan Micic, Joel Pekow, Henit Yanai, Russel D. Cohen, Iris Dotan, David T. Rubin, Atsushi Sakuraba

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Short survey › peer-review

11 Scopus citations

Original language	English
Pages (from-to)	2444-2446.e2
Journal	Clinical Gastroenterology and Hepatology
Volume	19
Issue number	11
DOIs	https://doi.org/10.1016/j.cgh.2020.10.035
State	Published - Nov 2021

Funding

Funders	Funder number
AbbVie Laboratories
Aerpio Therapeutics
Board of Trustees
Cornerstones Health, Inc.
Prometheus Laboratories
RedHill Biopharma
Techlab Inc
Vital Therapeutics
Boehringer Ingelheim
Crohn's and Colitis Foundation of America
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Genentech
Sanofi
Schawarz Pharma
Gilead Sciences
Celgene
AbbVie
American College of Gastroenterology
Neos Therapeutics

Access to Document

10.1016/j.cgh.2020.10.035

Cite this

Ollech, J. E., Avni-Biron, I., Glick, L., Haider, H., Dalal, S. R., Micic, D., Pekow, J., Yanai, H., Cohen, R. D., Dotan, I., Rubin, D. T., & Sakuraba, A. (2021). Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clinical Gastroenterology and Hepatology, 19(11), 2444-2446.e2. https://doi.org/10.1016/j.cgh.2020.10.035

@article{14cf4cd86ba049bbac696625d842c8d1,

title = "Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes",

author = "Ollech, {Jacob E.} and Irit Avni-Biron and Laura Glick and Haider Haider and Dalal, {Sushila R.} and Dejan Micic and Joel Pekow and Henit Yanai and Cohen, {Russel D.} and Iris Dotan and Rubin, {David T.} and Atsushi Sakuraba",

note = "Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts. Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts.",

year = "2021",

month = nov,

doi = "10.1016/j.cgh.2020.10.035",

language = "אנגלית",

volume = "19",

pages = "2444--2446.e2",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "11",

}

Ollech, JE, Avni-Biron, I, Glick, L, Haider, H, Dalal, SR, Micic, D, Pekow, J, Yanai, H, Cohen, RD, Dotan, I, Rubin, DT & Sakuraba, A 2021, 'Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes', Clinical Gastroenterology and Hepatology, vol. 19, no. 11, pp. 2444-2446.e2. https://doi.org/10.1016/j.cgh.2020.10.035

TY - JOUR

T1 - Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes

AU - Ollech, Jacob E.

AU - Avni-Biron, Irit

AU - Glick, Laura

AU - Haider, Haider

AU - Dalal, Sushila R.

AU - Micic, Dejan

AU - Pekow, Joel

AU - Yanai, Henit

AU - Cohen, Russel D.

AU - Dotan, Iris

AU - Rubin, David T.

AU - Sakuraba, Atsushi

N1 - Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts. Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85097456818&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2020.10.035

DO - 10.1016/j.cgh.2020.10.035

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???

C2 - 33223497

AN - SCOPUS:85097456818

SN - 1542-3565

VL - 19

SP - 2444-2446.e2

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 11

ER -

Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes

Funding

Access to Document

Other files and links

Cite this